Clinical Trials Logo

Filter by:
NCT ID: NCT01234688 Completed - Clinical trials for Kidney Failure, Chronic

Effects of Aerobic Training in End Stage Renal Disease Patients

Start date: June 2008
Phase: N/A
Study type: Interventional

The investigators raised the hypothesis that exercise training would be associated with improvement in exercise tolerance and VO2 kinetics in hemodialysis patients.

NCT ID: NCT01234311 Completed - Prostate Cancer Clinical Trials

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Start date: March 2011
Phase: Phase 3
Study type: Interventional

This is a Phase 3 randomized, double blind, placebo controlled study of tasquinimod in asymptomatic to mildly symptomatic patients with metastatic CRPC to confirm the effect of tasquinimod on delaying disease progression compared with placebo. Approximately 1200 eligible patients with metastatic CRPC will be randomly assigned in a 2:1 ratio to 1 of 2 treatment groups: Treatment Group A (tasquinimod 0.25, 0.5, or 1 mg/day; n=800) or Treatment Group B (placebo; n=400).

NCT ID: NCT01232634 Completed - Hemophilia Clinical Trials

Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles

Start date: September 2010
Phase: Phase 2
Study type: Observational

The purpose of this study is to test the external validity of the systemic ultrasound protocol for data acquisition and interpretation, in order to diagnose soft tissue and osteochondral abnormalities in hemophilic children.

NCT ID: NCT01232569 Completed - Clinical trials for Rheumatoid Arthritis

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Start date: March 2011
Phase: Phase 3
Study type: Interventional

This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.

NCT ID: NCT01232452 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

A Study in Non-Small Cell Lung Cancer

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).

NCT ID: NCT01231620 Completed - Influenza, Human Clinical Trials

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

ZORO
Start date: January 15, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu. Zanamivir will be compared with oseltamivir, which is used for treating flu.

NCT ID: NCT01231516 Completed - HIV Infections Clinical Trials

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

SAILING
Start date: October 26, 2010
Phase: Phase 3
Study type: Interventional

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.

NCT ID: NCT01231477 Completed - Sevoflurane Clinical Trials

Cytokines and Sevoflurane During Surgery

Start date: July 2009
Phase: N/A
Study type: Observational

The aim of the present study was to evaluate the effects of anaesthesia with sevoflurane and surgery on cytokines response.

NCT ID: NCT01231243 Completed - Tooth Discoloration Clinical Trials

Clinical Effectiveness of In-office Bleaching Activated With a LED/Laser Device

Start date: January 2011
Phase: Phase 4
Study type: Interventional

There is a controversy in the dentistry literature about how the use of associated light to activate 35% hydrogen peroxide gel during in-office tooth bleaching may increase the bleaching effectiveness. The studies that demonstrated an increased level of bleaching using light activation employed lower hydrogen peroxide gels while the ones reporting no statistical difference employed higher hydrogen peroxide gels. The hypothesis of this study is that the effectiveness of light activation tooth bleaching in dependent on the hydrogen peroxide concentration employed.

NCT ID: NCT01231126 Completed - Pregnancy Clinical Trials

Evaluation the Blood Loss in Pregnancies With Misoprostol-induced Labour

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the blood loss in induced vaginal delivery by misoprostol and caesarians section with induction attempt.